+89%

est. 2Y upside i

HealthcareSeries A

Seed Health is a microbiome science company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions. All consumer innovations in probiotics are commercialized under Seed®.

Rank

#106

Sector

Biotechnology / Consumer Health

Est. Liquidity

~2Y

Data Quality

Data: Medium

Seed Health presents a strong upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (40%)+350%

Seed Health is acquired at a significant premium, or continues its rapid growth (43% YoY) and strong profitability (EBITDA over $50M) for two more years, reaching approximately $409M in revenue. This performance, driven by expanding product lines like Co-Biotics and successful market penetration in major retailers, justifies a $4.5B valuation.

Base (35%)+100%

Seed Health is acquired at or slightly above its current target valuation of $1.0B, or continues to grow steadily, reaching approximately $409M in revenue in two years. This scenario assumes continued market leadership in scientifically-validated probiotics but faces ongoing competition and regulatory scrutiny, leading to a $2.0B valuation.

Bear (25%)-70%

The planned sale falls through, growth significantly decelerates due to increased competition from large incumbents or new regulatory hurdles, or market commoditization intensifies. This leads to a down round or acquisition at $300M, severely impacting common stock value.

Est. time to liquidity~1.5 years

Preference Stack Risk

low

Funding Intensity

4%

Investors hold $44M in liquidation preferences, which is a small fraction (4.4%) of the current $1.0B valuation.

Dilution Risk

moderate

While profitable and exploring a sale, if an acquisition does not occur, future funding rounds could lead to additional dilution for common shareholders.

Secondary Liquidity

limited

As a private company, secondary liquidity is generally limited, though a potential acquisition could offer an exit for existing equity holders.

View all 5 open roles at Seed →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Seed's data — designed to show you've done your homework.

  • 1

    “Given the active exploration of a sale, how is Seed Health preparing for potential integration challenges or maintaining its scientific culture under new ownership?”

  • 2

    “With the launch of Co-Biotics and continued expansion of SeedLabs, how does the company prioritize R&D investments across its diverse product pipeline and environmental initiatives?”

  • 3

    “Considering the strong growth in retail partnerships like Target and Sprouts, what are the key strategies for scaling operations and supply chain to meet increasing demand while maintaining product quality and scientific integrity?”

  • 4

    “What is the company's philosophy on employee equity given the potential acquisition, and are there any plans for secondary liquidity or refresh grants post-acquisition?”

Community

Valuation Sentiment

Our model estimates +89% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.